Views & Analysis | Perspectives on pharma industry issues

Digital

Abstract AI concept, turquoise hexagonals on dark background

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

R&D

A certificate of analysis should be evidence, not a sales do...

Regulators weighing peptide bulk substances can ask whether today's documentation rules fit the risks of this supply chain.

R&D

From phase 1 to phase 3: Scaling radiopharmaceutical trials

Success in radiopharmaceutical development depends on creating and maintaining an integrated, scalable system.

Patients

pharmaphorum podcast Episode 285, Donna Cryer, CryerHealth, LLC

Patients not just at the table, but creating their own: In c...

Donna Cryer, founding partner and Chief Patient Officer of CryerHealth, LLC discusses why is patient inclusion is not the same as patient leadership.

R&D

Gravity is an experimental variable pharma has rarely been a...

Microgravity should not be a destination for pharmaceutical R&D, but another experimental environment.

Articles

Social pharma faces: Atul Sharma

pharmaphorum spoke with Atul Sharma for a view of social media use in India. Isn’t it about time that emerging markets took social media more seriously? Atul certainly thinks so. The Indian pharmaceutical industry is the world's second-largest by volume and is set to lead the Indian manufacturing sector. So we felt it only...

Articles

pharmaphorum celebrates its first birthday!

As pharmaphorum celebrates its first birthday, Paul Tunnah reflects on a year of running a pharma social media site and looks forward to the future. Well, I can scarcely believe it myself, but pharmaphorum has reached its first birthday! The last year has certainly flown by, but...

Articles

Tunnah’s musings: has Facebook stopped us landing on the moo...

This month Paul Tunnah is stepping back to view the big picture and wonders whether we’re all getting too stuck in the short-term to deal with the really important issues. All the buzz this week has been about Facebook - about which pharma companies have kept their pages going and which have deserted the most popular …

Sales & Marketing

Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Digital

Sponsored

The hardest part of becoming an AI-first company: It’s not t...

Axtria president and CEO Jaswinder Chadha on the culture and governance decisions behind his company’s AI transformation.

Digital

Sponsored

Antiviral development in the age of AI: From pre-IND to earl...

hVIVO experts discuss how advancements in AI and machine learning are pushing industry beyond the bounds of a traditional "one virus, one drug" model.